C
Clara Ugolini
Researcher at University of Pisa
Publications - 130
Citations - 5031
Clara Ugolini is an academic researcher from University of Pisa. The author has contributed to research in topics: Thyroid carcinoma & Thyroid. The author has an hindex of 35, co-authored 106 publications receiving 4150 citations. Previous affiliations of Clara Ugolini include Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Rossella Elisei,Clara Ugolini,David Viola,Cristiana Lupi,Agnese Biagini,Riccardo Giannini,Cristina Romei,Paolo Miccoli,Aldo Pinchera,Fulvio Basolo +9 more
TL;DR: The BRAF(V600E) mutation was demonstrated to be a poor prognostic factor independent from other clinicopathological features in PTC patients, who were not only at a higher risk not to be cured but also for death.
Journal ArticleDOI
Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma
Cristiana Lupi,Riccardo Giannini,Clara Ugolini,Agnese Proietti,Piero Berti,Michele Minuto,Gabriele Materazzi,Rossella Elisei,Massimo Santoro,Paolo Miccoli,Fulvio Basolo +10 more
TL;DR: The data suggest that BRAF V600E mutation is associated with high-risk PTC and in particular in follicular variant with invasive tumor growth.
Journal ArticleDOI
Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role
Emilio Fiore,Teresa Rago,Maria Annateresa Provenzale,M Scutari,Clara Ugolini,Fulvio Basolo,G. Di Coscio,Piero Berti,Lucia Grasso,Rossella Elisei,Aldo Pinchera,P Vitti +11 more
TL;DR: The data confirm a direct relationship between TSH levels and risk of PTC in patients with nodular thyroid diseases and the presence of thyroid auto-antibodies (TAb) was associated with a significant increase of TSH.
Journal ArticleDOI
The BRAF V600E Mutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma: Single-Institution Results from a Large Cohort Study
Rossella Elisei,David Viola,Liborio Torregrossa,Riccardo Giannini,Cristina Romei,Clara Ugolini,Eleonora Molinaro,Laura Agate,Agnese Biagini,Cristiana Lupi,Laura Valerio,Gabriele Materazzi,Paolo Miccoli,Paolo Piaggi,Aldo Pinchera,Paolo Vitti,Fulvio Basolo +16 more
TL;DR: The BRAF(V600E) mutation was demonstrated to be a poor prognostic factor for the persistence of the disease independent from other clinical-pathological features in low-risk intrathyroid PTC patients, and could be useful to identify those who require less or more aggressive treatments.
Journal ArticleDOI
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Chiara Cremolini,Carlotta Antoniotti,Daniele Rossini,Sara Lonardi,Fotios Loupakis,Filippo Pietrantonio,Roberto Bordonaro,Tiziana Latiano,Emiliano Tamburini,Daniele Santini,Alessandro Passardi,Federica Marmorino,Roberta Grande,Giuseppe Aprile,Alberto Zaniboni,Sabina Murgioni,Cristina Granetto,Angela Buonadonna,Roberto Moretto,Salvatore Corallo,Stefano Cordio,Lorenzo Antonuzzo,Gianluca Tomasello,Gianluca Masi,Monica Ronzoni,Samantha Di Donato,Chiara Carlomagno,Matteo Clavarezza,Giuliana Ritorto,Andrea Mambrini,Mario Roselli,Samanta Cupini,Serafina Mammoliti,Elisabetta Fenocchio,Enrichetta Corgna,Vittorina Zagonel,Gabriella Fontanini,Clara Ugolini,Luca Boni,Alfredo Falcone,Filippo de Braud,Evaristo Maiello,Giovanni Luca Frassineti,Teresa Gamucci,Francesco Di Costanzo,Luca Gianni,Patrizia Racca,Giacomo Allegrini,Alberto Sobrero,Massimo Aglietta,Enrico Cortesi,Domenico Corsi,Alberto Ballestrero,Andrea Bonetti,Francesco Di Clemente,Enzo Maria Ruggeri,Fortunato Ciardiello,Marco Benasso,Stefano Vitello,Saverio Cinieri,Stefania Mosconi,Nicola Silvestris,Antonio Frassoldati,Samantha Cupini,Alessandro Bertolini,Giampaolo Tortora,Carmelo Bengala,Daris Ferrari,Antonia Ardizzoia,Carlo Milandri,Silvana Chiara,Gianpiero Romano,Stefania Miraglia,Laura Scaltriti,Francesca Pucci,Livio Blasi,Silvia Brugnatelli,Luisa Fioretto,A.S. Ribecco,Raffaella Longarini,Michela Frisinghelli,Maria Banzi +81 more
TL;DR: The triplet FOLFOXIRI showed improved outcomes for patients with metastatic colorectal cancer, compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab, but the actual benefit of the upfront exposure to the three cytotoxic drugs compared with a preplanned sequential strategy of doublets was not clear.